吉西他滨联合卡铂对照奈达铂一线方案治疗晚期非小细胞肺癌临床研究

目的探讨奈达铂替代顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法 60例初次确诊为非小细胞肺癌患者入组,随机分成卡铂组（30例）,给予吉西他滨1000mg/m2,d1,8,卡铂AUC=6,d1;奈达铂组（30例）,给予吉西他滨1000mg/m2,d1,8;奈达铂80mg/m2,d1;2组均每21天重复1次,连用2～4周期;化疗结束2周后复查,比较两组的有效率和不良反应发生率。结果 60例均可评价疗效,每例患者均可顺利完成4周期化疗。两组疗效对比差异无统计学意义。结论初步研究结果提示吉西他滨联合奈达铂与吉西他滨联合卡铂治疗晚期非小细胞肺癌的疗效大致相等,但是不良反应明显减少。

Clinical study on Gemcitabine plus Carboplatin versus Gemcitabine plus Nedaplatin as first-line treatment in advanced nonsmall-cell lung cancer

Objective Gemcitabine plus Carboplatin were effective regimen in treating non-small-cell lung cancer（NSCLC）,but Carboplatin had some severe adverse effects.The clinical trial was initiated to evaluate the effect and safety of Gemcitabine plus Nedaplatin for advanced NSCLC,by compared with Gemcitabine plus Carboplatin.Methods 60 patients with advanced NSCLC were randomized into two groups：the patients of Carboplatin group were treated with Gemcitabine 1 000mg/m2 d1,8,and Carboplatin AUC=6,d1;and the patients of Nedaplatin group were treat with Gemcitabine 1 000mg/m2 d1,8,and Nedaplatin 80mg/m2,d1.Both groups were repeated every 21 days and 2～4 cycles.The evaluation of the efficacy and safety was performed 2 weeks after chemotherapy regularly.Results All of 60 patients were evaluable and received 4 cycles chemotherapy.The were significance between two groups.Conclusion The regimen of Gemcitabine plus Nedaplatin have the same efficacy and less adverse response as compared to Gemcitabine plus Carboplatin in treatment for advanced NSCLC.